Drug Trial Radar · NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
12
Actual
Start
Sep 20, 2023
Primary completion
Jan 13, 2025
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- Evopoint Biosciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .
Conditions
- Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Urothelial Carcinoma
- Prostate Cancer
- Small-cell Lung Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Other Solid Tumors
Interventions
XNW5004Drug
XNW5004 an EZH2 inhibitor, BID, administered in continuous
KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for InjectionDrug
KEYTRUDA® (pembrolizumab) a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D) of XNW5004 in Combination With KEYTRUDA® (pembrolizumab) (Phase 1b Only)Time frame: The first 21-day cycle of therapy
- Objective Response Rate (ORR) (Phase 2)Time frame: Radiologic tumor assessments performed at baseline(within 28 days before start of study treatment)and every 9 weeks in the first 54 weeks (including the 54th week) after the first drug administration then every 12 weeks thereafter until confirmed disease
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center (SYSUCC)
Guangzhou, Guodong Province, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.